Department of Pharmacy & Therapeutics, University of Pittsburgh School of Pharmacy, Pennsylvania 15213, USA.
Paediatr Drugs. 2010;12(1):35-49. doi: 10.2165/11316180-000000000-00000.
Solid organ transplantation is a life-saving treatment for end-stage organ failure in children. Immunosuppressant medications are used to prevent rejection of the organ transplant. However, these medications are associated with significant adverse effects that impact growth and development, quality of life (QOL), and sometimes long-term survival after transplantation. Adverse effects can differ between the immunosuppressants, but many result from the overall state of immunosuppression. Strategies to manage immunosuppressant adverse effects often involve minimizing exposure to the drugs while balancing the risk for rejection. Early recognition of immunosuppressant adverse effects may help to reduce morbidities associated with solid organ transplantation, improve QOL, and possibly increase overall patient survival.
实体器官移植是治疗儿童终末期器官衰竭的一种救命疗法。免疫抑制剂用于预防器官移植排斥。然而,这些药物会产生重大的不良反应,影响生长发育、生活质量(QOL),有时还会影响移植后的长期生存。免疫抑制剂的不良反应各有不同,但许多不良反应是由于整体免疫抑制状态引起的。管理免疫抑制剂不良反应的策略通常包括在平衡排斥风险的同时,尽量减少药物暴露。早期识别免疫抑制剂的不良反应可能有助于减少与实体器官移植相关的发病率,提高生活质量,并可能增加整体患者生存率。